Research progress in acetyl-CoA carboxylase inhibitors

MEI Liankuo; WEI Qiangqiang; ZHANG Huibin; ZHOU Jinpei

doi:10.11665/j.issn.1000-5048.20190301

Journal of China Pharmaceutical University > 2019 > 50(3): 253-264. > DOI: 10.11665/j.issn.1000-5048.20190301

MEI Liankuo, WEI Qiangqiang, ZHANG Huibin, ZHOU Jinpei. Research progress in acetyl-CoA carboxylase inhibitors[J]. Journal of China Pharmaceutical University, 2019, 50(3): 253-264. DOI: 10.11665/j.issn.1000-5048.20190301

Citation:

PDF (1791 KB)

Research progress in acetyl-CoA carboxylase inhibitors

More Information

Graphical Abstract

Abstract

Abstract

Non-alcoholic fatty liver disease(NAFLD)is characterized by excessive fat deposition in hepatocytes, fat accumulates mainly in the form of triglycerides, triglycerides derive from esterification of glycerol and free fatty acids; and the synthesis of fatty acid is abnormally active in tumor cells, which is significantly higher than that of normal cells, providing necessary lipid substrates for the formation of biofilms, the production of signaling molecules and energy during the proliferation and development of tumor cells. Acetyl-CoA carboxylase(ACC)is the limiting-rate enzyme of de novo lipogenesis. And it is also an enzyme that catalyzes the first step of the fatty acid synthesis pathway; its catalyzed product, malonyl-CoA, also inhibits the oxidation of fatty acids. ACC inhibition can reduce fatty acid synthesis and promote fatty acid oxidation, which reduce the amount of fatty acids in the body. Hence, attenuating fat accumulation could improve NAFLD, and reduction of fatty acid content inhibits development of tumor tissues because lipid substrates could not satisfy the requirement of cancer cells. Therefore, ACC inhibitors have potential to be the novel drugs that can treat NAFLD and cancer. The recent research progress on ACC inhibitors is reviewed in this paper.
- acetyl-CoA carboxylase,
- acetyl-CoA carboxylase inhibitors,
- non-alcoholic fatty liver disease,
- tumor,
- progress

FullText(HTML)

References (49)

References

[1]	Pascale A,Pais R,Ratziu V,et al.An overview of nonalcoholic steatohepatitis:past,present and future directions[J].J Gastrointestin Liver Dis,2010,19(4):415-423.
[2]	Fan JG.Epidemiology of alcoholic and nonalcoholic fatty liver disease in China[J].J Gastroenterol Hepatol,2013,28(Suppl 1):11-17.
[3]	Feldstein AE,Charatcharoenwitthaya P,Treeprasertsuk S,et al.The natural history of non-alcoholic fatty liver disease in children:a follow-up study for up to 20 years[J].Gut,2009,58(11):1538-1544.
[4]	Wattacheril J,Issa D,Sanyal A,et al.Nonalcoholic steatohepatitis(NASH)and hepatic fibrosis:emerging therapies[J].Annu Rev Pharmacol Toxicol,2018,58(1):649-662.
[5]	Fabbrini E,Sullivan S,Klein S,et al.Obesity and nonalcoholic fatty liver disease:biochemical,metabolic,and clinical implications[J].Hepatology,2010,51(2):679-689.
[6]	Medes G,Thomas A,Weinhouse S,et al.Metabolism of neoplastia tissue.IV.A study of lipid synthesis in neoplastia tissue slices in vitro[J].Cancer Res,1953,13(1):27-29.
[7]	Currie E,Schulze A,Zechner R,et al.Cellular fatty acid metabolism and cancer[J].Cell Metab,2013,18(2):153-161.
[8]	Mounier C,Bouraoui L,Rassart E,et al.Lipogenesis in cancer progression[J].Int J Oncol,2014,45(2):485-492.
[9]	Kim J,DeBerardinis RJ.Blocking fatty acid synthesis reduces lung tumor growth in mice[J].Nature Medicine,2016,22(10):1077-1078.
[10]	Martinez UE,Peiris M,Pestell RG,et al.Cancer metabolism:a therapeutic perspective[J].Nat Rev Clin Oncol,2017,14(1):11-31.
[11]	Samuel VT,Shulman GI.Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases[J].Cell Metab,2018,27(1):22-41.
[12]	Francis P.Kuhajda M.Fatty-acid synthase and human cancer:new perspectives on its role in tumor biology[J].Nutrition,2000,16(3):202-208.
[13]	Blank HM,Maitra M,Polymenis M,et al.Lipid biosynthesis:when the cell cycle meets protein synthesis[J].Cell Cycle,2017,16(10):905-906.
[14]	Yu LP,Kim YS,Tong L,et al.Mechanism for the inhibition of the carboxyltransferase domain of acetyl-coenzyme A carboxylase by pinoxaden[J].Proc Natl Acad Sci U S A,2010,107(51):22072-22077.
[15]	Zhang H,Tweel B,Tong L,et al.Molecular basis for the inhibition of the carboxyltransferase domain of acetyl-coenzyme-A carboxylase by haloxyfop and diclofop[J].Proc Natl Acad Sci U S A,2004,101(16):5910-5915.
[16]	Zhang H,Yang Z,Shen Y,et al.Crystal structure of the carboxyltransferase domain of acetyl-coenzyme A carboxylase[J].Science,2003,299(5615):2064-2067.
[17]	Corbett JW,Freeman-Cook KD,Elliott R,et al.Discovery of small molecule isozyme non-specific inhibitors of mammalian acetyl-CoA carboxylase 1 and 2[J].Bioorg Med Chem Lett,2010,20(7):2383-2388.
[18]	Tong L. Acetyl-coenzyme A carboxylase: crucial metabolic enzyme and attractive target for drug discovery[J].Cell Mol Life Sci,2005,62(16):1784-1803.
[19]	Tong L,Harwood HJ Jr.Acetyl-coenzyme A carboxylases:versatile targets for drug discovery[J].J Cell Biochem,2006,99(6):1476-1488.
[20]	Fullerton MD,Galic S,Marcinko K,et al.Single phosphorylation sites in ACC1 and ACC2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin[J].Nat Med,2013,19(12):1649-1654.
[21]	Bengtsson C,Blaho S,Saitton DB,et al.Design of small molecule inhibitors of acetyl-CoA carboxylase 1 and 2 showing reduction of hepatic malonyl-CoA levels in vivo in obese Zucker rats[J].Bioorg Med Chem,2011,19(10):3039-3053.
[22]	Mcgarry JD,Leatherman GF,Foster DW,et al.Carnitine palmitoyltransferase 1.the site of inhibition of hepatic fatty acid oxidation by malonyl-CoA[J].J Biol Chem,1978,253(12):4128-4136.
[23]	Cho YS,Lee JI,Shin D,et al.Molecular mechanism for the regulation of human ACC2 through phosphorylation by AMPK[J].Biochem Biophys Res Commun,2010,391(1):187-192.
[24]	Harwood HJ.Treating the metabolic syndrome:acetyl-CoA carboxylase inhibition[J].Expert Opin 2005,9(2):267-281.
[25]	Shen Y, Volrath SL, Weatherly SC, et al. A mechanism for the potent inhibition of eukaryotic acetyl-coenzyme A carboxylase by soraphen A,a macrocyclic polyketide natural product[J].Mol Cell,2004,16(6):881-891.
[26]	Harwood HJ Jr.,Petras SF,Shelly LD,et al.Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations,inhibit fatty acid synthesis,and increase fatty acid oxidation in cultured cells and in experimental animals[J].J Biol Chem,2003,278(39):37099-37111.
[27]	Zhang H,Tweel B,Li J,et al.Crystal structure of the carboxyltransferase domain of acetyl-coenzyme A carboxylase in complex with CP-640186[J].Structure,2004,12(9):1683-1691.
[28]	Griffith DA,Kung DW,Esler WP,et al.Decreasing the rate of metabolic ketone reduction in the discovery of a clinical acetyl-CoA carboxylase inhibitor for the treatment of diabetes[J].J Med Chem,2014,57(24):10512-10526.
[29]	Kim CW, Addy C, Kusunoki J, et al. Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans:a bedside to bench investigation[J].Cell Metab,2017,26(2):394-406.
[30]	Abel R,Mondal S,Masse C,et al.Accelerating drug discovery through tight integration of expert molecular design and predictive scoring[J].Curr Opin Struct Biol,2017,43:38-44.
[31]	Harriman G,Greenwood J,Bhat S,et al.Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis,improves insulin sensitivity,and modulates dyslipidemia in rats[J].PNAS,2016,113(13):E1976-E1805.
[32]	Svensson RU,Parker SJ,Eichner LJ,et al.Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models[J].Nat Med,2016,22(10):1108-1119.
[33]	Lally JSV,Ghoshal S,DePeralta DK,et al.Inhibition of acetyl-CoA carboxylase by phosphorylation or the inhibitor ND-654 suppresses lipogenesis and hepatocellular carcinoma[J].Cell Metab,2018,29(1):1-9.
[34]	Ratner M.Gilead bets big on Nimbus′ fatty liver disease drug[J].Nat Biotechnol,2016,34(6):575-576.
[35]	Stiede K,Miao W,Blanchette HS,et al.Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects:a randomized,double-blind,crossover study[J].Hepatology,2017,66(2):324-334.
[36]	Loomba R,Kayali Z,Noureddin M,et al.GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease[J].Gastroenterology,2018,155(5):1463-1473.
[37]	Petrova E,Scholz A,Paul J,et al.Acetyl-CoA carboxylase inhibitors attenuate WNT and Hedgehog signaling and suppress pancreatic tumor growth[J].Oncotarget,2017,8(30):48660-48670.
[38]	Yamashita T,Kamata M,Endo S,et al.Design,synthesis,and structure-activity relationships of spirolactones bearing 2-ureidobenzothiophene as acetyl-CoA carboxylases inhibitors[J].Bioorg Med Chem Lett,2011,21(21):6314-6318.
[39]	Kamata M,Yamashita T,Kina A,et al.Design,synthesis,and structure-activity relationships of novel spiro-piperidines as acetyl-CoA carboxylase inhibitors[J].Bioorg Med Chem Lett,2012,22(11):3643-3647.
[40]	Kamata M,Yamashita T,Kina A,et al.Symmetrical approach of spiro-pyrazolidinediones as acetyl-CoA carboxylase inhibitors[J].Bioorg Med Chem Lett,2012,22(14):4769-4772.
[41]	Mizojiri R,Asano M,Tomita D,et al.Discovery of novel selective acetyl-CoA carboxylase(ACC)1 inhibitors[J].J Med Chem,2018,61(3):1098-1117.
[42]	Chonan T,Tanaka H,Yamamoto D,et al.Design and synthesis of disubstituted(4-piperidinyl)-piperazine derivatives as potent acetyl-CoA carboxylase inhibitors[J].Bioorg Med Chem Lett,2010,20(13):3965-3968.
[43]	Chonan T,Wakasugi D,Yamamoto D,et al.Discovery of novel(4-piperidinyl)-piperazines as potent and orally active acetyl-CoA carboxylase 1/2 non-selective inhibitors:F-Boc and triF-Boc groups are acid-stable bioisosteres for the Boc group[J].Bioorg Med Chem,2011,19(5):1580-1593.
[44]	Keil S,Muller M,Zoller G,et al.Identification and synthesis of novel inhibitors of acetyl-CoA carboxylase with in vitro and in vivo efficacy on fat oxidation[J].J Med Chem,2010,53(24):8679-8687.
[45]	Lovering F,Bikker J,Humblet C,et al..Escape from flatland:increasing saturation as an approach to improving clinical success[J].J Med Chem,2009,52(21):6752-6756.
[46]	Bourbeau MP,Siegmund A,Allen JG,et al.Piperazine oxadiazole inhibitors of acetyl-CoA carboxylase[J].J Med Chem,2013,56(24):10132-10141.
[47]	Nishiura Y, Matsumura A, Kobayashi N, et al. Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy[J].Bioorg Med Chem Lett,2018,28(14):2498-2503.
[48]	Jasmina M,Dominika C,Caroline P,et al.Recombinant yeast screen for new inhibitors of human acetyl-CoA carboxylase 2 identifies potential drugs to treat obesity[J].PNAS,2010,107(20):9093-9098.
[49]	Jump DB,Torres-Gonzalez M,Olson LK,et al.Soraphen A,an inhibitor of acetyl CoA carboxylase activity,interferes with fatty acid elongation[J].Biochem Pharmacol,2011,81(5):649-660.

[1]	JIA Yifei, WANG Yamei, LI Gongyu. Recent progress of protein glycosylation characterization utilizing native conformer-resolved mass spectrometry[J]. Journal of China Pharmaceutical University, 2023, 54(6): 674-681. DOI: 10.11665/j.issn.1000-5048.2023060901
[2]	TIAN Zhixin. Progresses of mass spectrometry-based analysis of N-glycoproteins[J]. Journal of China Pharmaceutical University, 2023, 54(6): 662-673. DOI: 10.11665/j.issn.1000-5048.2023062701
[3]	LI Chengfei, CHEN Ling, WU Xuri. Regio-selective glycosylation of mogroside IIIE by glycosyltransferase[J]. Journal of China Pharmaceutical University, 2019, 50(2): 222-229. DOI: 10.11665/j.issn.1000-5048.20190214
[4]	JIN Yue, WU Xuri, CHEN Yijun. Applications of glycosyltransferases in the improvement of druggability of natural products[J]. Journal of China Pharmaceutical University, 2017, 48(5): 529-535. DOI: 10.11665/j.issn.1000-5048.20170504
[5]	HU Jing, FAN Hua, YIN Jian. Effects of N-acyl glucosamines on GABA uptake activity of GABA transporter 1[J]. Journal of China Pharmaceutical University, 2016, 47(2): 228-234. DOI: 10.11665/j.issn.1000-5048.20160217
[6]	WANG Yuanxi, CHEN Junsheng, SHAO Lei, LI Ji′an, LIN Huimin, CHEN Daijie. Heterologous expression and in vitro activity of vancomycin glycosyltransferase GtfE[J]. Journal of China Pharmaceutical University, 2013, 44(3): 272-276. DOI: 10.11665/j.issn.1000-5048.20130317
[7]	Tumor microenvironment：A novel target for antitumor activity of polysaccharides[J]. Journal of China Pharmaceutical University, 2010, 41(1): 1-10.
[9]	YANG Ya-Bo, WANG Min, LIANG Yan, LIANG Jing-Yu. Transgalactosylation of Isotaxiresinol by[J]. Journal of China Pharmaceutical University, 2002, (6).
[10]	Effect of ADP-Ribosylation on Transcriptional Activities in Nuclei from Rat Liver and Spleen[J]. Journal of China Pharmaceutical University, 1991, (4): 229-232.

Cited By

Get Citation

PDF

XML

Article views (2432) PDF downloads (3457)

Turn off MathJax

Article Contents

Abstract

References

Research progress in acetyl-CoA carboxylase inhibitors

Abstract

References

Related Articles

Catalog

Research progress in acetyl-CoA carboxylase inhibitors

Abstract

References

Related Articles

Catalog

Export File

Citation

Format

Content